KR20090057032A - 사이토카인 매개 질환의 치료에 유용한 피롤 유도체 - Google Patents
사이토카인 매개 질환의 치료에 유용한 피롤 유도체 Download PDFInfo
- Publication number
- KR20090057032A KR20090057032A KR1020097005765A KR20097005765A KR20090057032A KR 20090057032 A KR20090057032 A KR 20090057032A KR 1020097005765 A KR1020097005765 A KR 1020097005765A KR 20097005765 A KR20097005765 A KR 20097005765A KR 20090057032 A KR20090057032 A KR 20090057032A
- Authority
- KR
- South Korea
- Prior art keywords
- pyridin
- pyrrole
- piperazin
- carbonitrile
- phenyl
- Prior art date
Links
- 0 CC(C(c1c(CCN)[n]c(-c2cc(-c3c*(OC)cnc3)ncc2)c1)O)O Chemical compound CC(C(c1c(CCN)[n]c(-c2cc(-c3c*(OC)cnc3)ncc2)c1)O)O 0.000 description 1
- SYDSFMHWCSBTRL-UHFFFAOYSA-N CC(C(c1cc(Cl)ncc1)=O)Br Chemical compound CC(C(c1cc(Cl)ncc1)=O)Br SYDSFMHWCSBTRL-UHFFFAOYSA-N 0.000 description 1
- UKTLRXVHICYNOI-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c([nH]c(-c1cc(-c2cccc(NC(C)=O)c2)ncc1)c1)c1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c([nH]c(-c1cc(-c2cccc(NC(C)=O)c2)ncc1)c1)c1C#N)=O UKTLRXVHICYNOI-UHFFFAOYSA-N 0.000 description 1
- RDIAGLGFTVUUSA-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c([nH]c(-c1cc(Nc(cc2)ccc2N2CCOCC2)ncc1)c1)c1C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c([nH]c(-c1cc(Nc(cc2)ccc2N2CCOCC2)ncc1)c1)c1C#N)=O RDIAGLGFTVUUSA-UHFFFAOYSA-N 0.000 description 1
- RXCAKNXOVNDNNH-UHFFFAOYSA-N CN(CC1)CCN1c(nc1)ccc1-c1nccc(-c([nH]2)cc(C(N)=O)c2N2CCNCC2)c1 Chemical compound CN(CC1)CCN1c(nc1)ccc1-c1nccc(-c([nH]2)cc(C(N)=O)c2N2CCNCC2)c1 RXCAKNXOVNDNNH-UHFFFAOYSA-N 0.000 description 1
- IDKNGBSYHJMURN-UHFFFAOYSA-N CN(CCOC)c(nc1)ncc1-c1nccc(-c([nH]2)cc(C#N)c2N2CCNCC2)c1 Chemical compound CN(CCOC)c(nc1)ncc1-c1nccc(-c([nH]2)cc(C#N)c2N2CCNCC2)c1 IDKNGBSYHJMURN-UHFFFAOYSA-N 0.000 description 1
- JJLCNEOPNGKTQE-UHFFFAOYSA-N COCCOc1cncc(Br)c1 Chemical compound COCCOc1cncc(Br)c1 JJLCNEOPNGKTQE-UHFFFAOYSA-N 0.000 description 1
- SBCIOFYIDKTCHA-QPJJXVBHSA-N CS(N(CC1)C[IH]N1c([nH]c(-c1cc(/C=C/c(cc2)ccc2F)ncc1)c1)c1C#N)(=O)=O Chemical compound CS(N(CC1)C[IH]N1c([nH]c(-c1cc(/C=C/c(cc2)ccc2F)ncc1)c1)c1C#N)(=O)=O SBCIOFYIDKTCHA-QPJJXVBHSA-N 0.000 description 1
- XEBBUFKTMCCHCL-UHFFFAOYSA-N N#Cc(cc(-c1cc(-c(cc2)ccc2C(N2CCCC2)=O)ncc1)[nH]1)c1N1CCNCC1 Chemical compound N#Cc(cc(-c1cc(-c(cc2)ccc2C(N2CCCC2)=O)ncc1)[nH]1)c1N1CCNCC1 XEBBUFKTMCCHCL-UHFFFAOYSA-N 0.000 description 1
- OCEYUEBQFSPFOT-VMPITWQZSA-N N#Cc(cc(-c1ccnc(/C=C/c(cc2)ccc2F)c1)[nH]1)c1N1CCCC1 Chemical compound N#Cc(cc(-c1ccnc(/C=C/c(cc2)ccc2F)c1)[nH]1)c1N1CCCC1 OCEYUEBQFSPFOT-VMPITWQZSA-N 0.000 description 1
- CPHCPGMODSOXBA-UHFFFAOYSA-N NC(c(cc(-c1cc(-c2cc(cccc3)c3nc2)ncc1)[nH]1)c1N1CCNCC1)=O Chemical compound NC(c(cc(-c1cc(-c2cc(cccc3)c3nc2)ncc1)[nH]1)c1N1CCNCC1)=O CPHCPGMODSOXBA-UHFFFAOYSA-N 0.000 description 1
- SGIRKTUAPPIKID-VMPITWQZSA-N NC(c(cc(-c1cc(/C=C/c(cc2)ccc2F)ncc1)[nH]1)c1N1CCCC1)=O Chemical compound NC(c(cc(-c1cc(/C=C/c(cc2)ccc2F)ncc1)[nH]1)c1N1CCCC1)=O SGIRKTUAPPIKID-VMPITWQZSA-N 0.000 description 1
- MKTUVBDUUJYFCU-VOTSOKGWSA-N NC(c(cc(-c1cc(/C=C/c2ccccc2)ncc1)[nH]1)c1N1CCNCC1)=O Chemical compound NC(c(cc(-c1cc(/C=C/c2ccccc2)ncc1)[nH]1)c1N1CCNCC1)=O MKTUVBDUUJYFCU-VOTSOKGWSA-N 0.000 description 1
- VLPAFVJPFHZSQA-UHFFFAOYSA-N NC(c(cc(-c1ccnc(-c(cc2)ccc2NC(N2CCOCC2)=O)c1)[nH]1)c1N1CCNCC1)=O Chemical compound NC(c(cc(-c1ccnc(-c(cc2)ccc2NC(N2CCOCC2)=O)c1)[nH]1)c1N1CCNCC1)=O VLPAFVJPFHZSQA-UHFFFAOYSA-N 0.000 description 1
- RBMDNKKKYHIRKU-UHFFFAOYSA-N NCCc([nH]c(-c1cc(-c2cc(cccc3)c3nc2)ncc1)c1)c1C#N Chemical compound NCCc([nH]c(-c1cc(-c2cc(cccc3)c3nc2)ncc1)c1)c1C#N RBMDNKKKYHIRKU-UHFFFAOYSA-N 0.000 description 1
- XGRVWOUMFKGMJG-VOTSOKGWSA-N NCc([nH]c(-c1cc(/C=C/c2ccccc2)ncc1)c1)c1C#N Chemical compound NCc([nH]c(-c1cc(/C=C/c2ccccc2)ncc1)c1)c1C#N XGRVWOUMFKGMJG-VOTSOKGWSA-N 0.000 description 1
- FOILRISEUSBXSX-VOTSOKGWSA-N NCc([nH]c(-c1cc(/C=C/c2ccccc2)ncc1)c1)c1C(N)=O Chemical compound NCc([nH]c(-c1cc(/C=C/c2ccccc2)ncc1)c1)c1C(N)=O FOILRISEUSBXSX-VOTSOKGWSA-N 0.000 description 1
- GHYWEGDBGPDLCV-MTGFJVSHSA-N N[C@H](CC1)CN1c([nH]c(-c1ccnc(/C=C/c(cc2)ccc2F)c1)c1)c1C#N Chemical compound N[C@H](CC1)CN1c([nH]c(-c1ccnc(/C=C/c(cc2)ccc2F)c1)c1)c1C#N GHYWEGDBGPDLCV-MTGFJVSHSA-N 0.000 description 1
- BTYBRFUUMKPJBU-UHFFFAOYSA-N Nc(cc(-c1ccnc(-c2ccc(N(CC3)CCN3C3CCCC3)nc2)c1)[nH]1)c1N1CCNCC1 Chemical compound Nc(cc(-c1ccnc(-c2ccc(N(CC3)CCN3C3CCCC3)nc2)c1)[nH]1)c1N1CCNCC1 BTYBRFUUMKPJBU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06121036.5 | 2006-09-21 | ||
EP06121036 | 2006-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20090057032A true KR20090057032A (ko) | 2009-06-03 |
Family
ID=37684420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097005765A KR20090057032A (ko) | 2006-09-21 | 2007-09-19 | 사이토카인 매개 질환의 치료에 유용한 피롤 유도체 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100105664A1 (ru) |
EP (1) | EP2069333A1 (ru) |
JP (1) | JP2010504295A (ru) |
KR (1) | KR20090057032A (ru) |
CN (1) | CN101516874A (ru) |
AU (1) | AU2007299261A1 (ru) |
BR (1) | BRPI0717097A2 (ru) |
CA (1) | CA2662359A1 (ru) |
MX (1) | MX2009003081A (ru) |
RU (1) | RU2009114747A (ru) |
WO (1) | WO2008034600A1 (ru) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7922696B2 (en) | 2007-01-24 | 2011-04-12 | Access Scientific, Inc. | Access device |
AU2008242650A1 (en) | 2007-04-18 | 2008-10-30 | Access Scientific, Inc. | Access device |
WO2011097639A2 (en) | 2010-02-08 | 2011-08-11 | Access Scientific, Inc. | Access device |
WO2011101865A2 (en) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Stable pharmaceutical compositions of clopidogrel for parenteral delivery |
WO2014165127A1 (en) * | 2013-03-12 | 2014-10-09 | Abbvie Inc. | Pyrrole amide inhibitors |
US9566087B2 (en) | 2013-03-15 | 2017-02-14 | Access Scientific, Llc | Vascular access device |
DK3013796T3 (da) * | 2013-06-27 | 2020-03-16 | Lg Chemical Ltd | Biarylderivater som gpr120-agonister |
BR112016018691A2 (pt) * | 2014-02-14 | 2017-08-08 | Univ British Columbia | Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso |
US11261186B2 (en) * | 2014-12-24 | 2022-03-01 | Lg Chem. Ltd. | Biaryl derivative as GPR120 agonist |
WO2016176065A1 (en) | 2015-04-30 | 2016-11-03 | Access Scientific, Llc | Vascular access device |
JP2020532551A (ja) * | 2017-09-03 | 2020-11-12 | アンジオン バイオメディカ コーポレーション | Rho関連コイルドコイルキナーゼ(ROCK)阻害剤としてのビニルヘテロ環 |
US10569059B2 (en) | 2018-03-01 | 2020-02-25 | Asspv, Llc | Guidewire retention device |
IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
WO2021142006A1 (en) * | 2020-01-07 | 2021-07-15 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997016442A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
AU3044197A (en) | 1996-07-11 | 1998-02-09 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin- and tnf antagonists |
US6372777B1 (en) | 1999-12-23 | 2002-04-16 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
JP2006514043A (ja) | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−2を阻害する化合物 |
-
2007
- 2007-09-19 CN CNA200780035142XA patent/CN101516874A/zh active Pending
- 2007-09-19 WO PCT/EP2007/008153 patent/WO2008034600A1/en active Application Filing
- 2007-09-19 CA CA002662359A patent/CA2662359A1/en not_active Abandoned
- 2007-09-19 AU AU2007299261A patent/AU2007299261A1/en not_active Abandoned
- 2007-09-19 JP JP2009528640A patent/JP2010504295A/ja active Pending
- 2007-09-19 US US12/442,264 patent/US20100105664A1/en not_active Abandoned
- 2007-09-19 BR BRPI0717097-1A patent/BRPI0717097A2/pt not_active Application Discontinuation
- 2007-09-19 RU RU2009114747/04A patent/RU2009114747A/ru not_active Application Discontinuation
- 2007-09-19 EP EP07818248A patent/EP2069333A1/en not_active Withdrawn
- 2007-09-19 KR KR1020097005765A patent/KR20090057032A/ko not_active Application Discontinuation
- 2007-09-19 MX MX2009003081A patent/MX2009003081A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101516874A (zh) | 2009-08-26 |
EP2069333A1 (en) | 2009-06-17 |
MX2009003081A (es) | 2009-04-01 |
AU2007299261A1 (en) | 2008-03-27 |
BRPI0717097A2 (pt) | 2013-11-26 |
RU2009114747A (ru) | 2010-10-27 |
CA2662359A1 (en) | 2008-03-27 |
WO2008034600A1 (en) | 2008-03-27 |
US20100105664A1 (en) | 2010-04-29 |
JP2010504295A (ja) | 2010-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20090057032A (ko) | 사이토카인 매개 질환의 치료에 유용한 피롤 유도체 | |
JP6841771B2 (ja) | Ccr2モジュレータ | |
AU2008289037B2 (en) | 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors | |
AU2014298017B2 (en) | Heterobicycloaryl RORC2 inhibitors and methods of use thereof | |
KR20010108504A (ko) | 치환 아졸 | |
JP2010514821A (ja) | 新規n,n’−2,4−ジアニリノピリミジン誘導体、薬物としてのその調製、基本的にikk阻害剤としての医薬組成物 | |
KR20100031619A (ko) | Mk2 억제제로서 유용한 헤테로시클릭 화합물 | |
EP3704106B1 (en) | Alkene compounds as farnesoid x receptor modulators | |
EP3704112B1 (en) | Alkene spirocyclic compounds as farnesoid x receptor modulators | |
KR20090021192A (ko) | 피페리딘 또는 피롤리딘의 우레아 유도체, 그의 제조법 및 그의 치료 용도 | |
TW202216686A (zh) | 藉由使egfr抑制劑與e3連接酶配位體結合來降解(egfr)以及使用方法 | |
KR20090046891A (ko) | 키나제 억제제로서의 피롤로 이소퀴놀린 | |
CN113906020A (zh) | 用于治疗皮肤病的缓激肽(bk)b2受体拮抗剂的(r)-3-(氯-5-氟-2-((4-(1h-吡唑-1-基)-2-甲基喹啉-8-基氧基)甲基)苯基)吗啉衍生物及相关的化合物 | |
JP2012513977A (ja) | 2−ピリジン−2−イル−ピラゾール−3(2h)−オンの誘導体、この調製および治療的使用 | |
KR20130091308A (ko) | Jnk 억제제 | |
AU2002334207B2 (en) | N-substituted hydroxpyrimidinone carboxamide inhibitors of HIV integrase | |
OA18716A (en) | Heterobicycloaryl RORC2 inhibitors and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |